Non-hematopoietic EPO-derived peptide researched for neuropathic pain and tissue repair.
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) — but engineered to keep EPO's tissue-protective and anti-inflammatory effects while removing its blood-building (and clot-raising) activity. It targets the innate repair receptor on damaged tissue.
Its most studied use is small-fiber neuropathy, including the nerve pain seen in sarcoidosis and diabetes. By calming inflammation and supporting nerve repair, it has reduced neuropathic pain and improved nerve-fiber measures in trials.
Because it deliberately avoids raising red blood cells, it sidesteps EPO's main danger, which makes its risk profile relatively favorable for an emerging compound — though long-term data is still limited.
Reduces small-fiber neuropathic pain and supports nerve repair.
Human-trial evidence in sarcoidosis-related neuropathy
Tissue-protective, anti-inflammatory action via the innate repair receptor.
Mechanistically distinct from EPO; preclinical and clinical interest
Studied in diabetic-neuropathy contexts.
Early clinical data
We rate every peptide honestly across four dimensions — and tell you what it's not.
Promising but early. Strong animal data and/or small/preliminary human studies, not yet confirmed in robust trials.
Men with small-fiber neuropathy or chronic neuropathic pain seeking a non-opioid option
Does not raise red blood cells like EPO, but monitor as a precaution. Emerging compound with limited long-term data.
Women with neuropathic pain (incl. sarcoidosis-related) or inflammation
Used by women for small-fiber neuropathy; no hormonal interactions reported. Avoid in pregnancy without guidance.
Used by women for small-fiber neuropathy; no hormonal interactions.
This section is always free and never locked.
Does not raise red-blood-cell count like EPO, but monitor as a precaution.
Emerging compound — limited long-term data.
The effects most commonly reported with ARA-290 (Cibinetide), when they tend to show up, and how to manage them.
Rotate sites and use clean technique; usually minor.
Typically transient — ease the loading dose if needed.
Hydrate; lower the dose if it persists.
Individual responses vary. Stop and consult a clinician for severe, persistent, or unexpected reactions.
14 steps with photos, pro tips, and a dosing calculator.
Unlock Full Guide7 days free. Then $24/month.
████████ ████
████████ ████
████████ ████
Dosing info requires Core or Pro
Unlock DosingAlways free. Never locked.
A preview of the member outcomes dashboard. Real, anonymized ARA-290 (Cibinetide) results populate here as the community logs data.
See aggregated results from real users — benefit ratings, common goals, side effect frequency, and more.
Unlock with Core or ProGet the complete step-by-step guide, personalized dosing, and daily tracking.
View Full GuidePepCompass provides educational information only. Nothing on this platform constitutes medical advice, diagnosis, or treatment. All content is for informational and research purposes only. Always consult a licensed healthcare provider before starting any peptide protocol. Individual results vary.